Algert Global LLC Grows Stock Position in Insulet Corporation $PODD

Key Points

• Algert Global LLC has increased its stake in Insulet Corporation by 10.2%, acquiring an additional 968 shares during the first quarter, bringing its total holdings to 10,450 shares valued at approximately $2.74 million.
• Insulet reported $1.17 earnings per share for the latest quarter, exceeding analysts' expectations by $0.25, with revenue growing 32.9% year-over-year to $649.10 million.
• Analysts have generally upgraded their ratings for Insulet, with a consensus of 16 "Buy" ratings and a target price of approximately $330.71.

Algert Global LLC boosted its stake in Insulet Corporation (NASDAQ:PODD - Free Report) by 10.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 10,450 shares of the medical instruments supplier's stock after buying an additional 968 shares during the period. Algert Global LLC's holdings in Insulet were worth $2,744,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock worth $2,276,553,000 after purchasing an additional 178,976 shares during the period. American Century Companies Inc. increased its stake in Insulet by 34.8% during the first quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock worth $302,686,000 after purchasing an additional 297,734 shares during the period. Northern Trust Corp increased its stake in Insulet by 20.5% during the fourth quarter. Northern Trust Corp now owns 738,811 shares of the medical instruments supplier's stock worth $192,881,000 after purchasing an additional 125,710 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Insulet by 4.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier's stock worth $177,096,000 after purchasing an additional 27,408 shares during the period. Finally, GAMMA Investing LLC increased its stake in Insulet by 27,298.6% during the first quarter. GAMMA Investing LLC now owns 664,141 shares of the medical instruments supplier's stock worth $1,744,100,000 after purchasing an additional 661,717 shares during the period.

Insulet Stock Performance

NASDAQ PODD traded up $2.92 on Friday, reaching $330.77. The stock had a trading volume of 499,504 shares, compared to its average volume of 705,185. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet Corporation has a 12-month low of $180.31 and a 12-month high of $334.18. The business's 50-day moving average price is $300.94 and its 200 day moving average price is $285.91. The stock has a market cap of $23.28 billion, a P/E ratio of 100.54, a price-to-earnings-growth ratio of 2.77 and a beta of 1.35.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating analysts' consensus estimates of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $649.10 million during the quarter, compared to analysts' expectations of $612.31 million. During the same quarter in the previous year, the business earned $0.55 earnings per share. The firm's revenue for the quarter was up 32.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities analysts expect that Insulet Corporation will post 3.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on PODD. Canaccord Genuity Group boosted their price target on shares of Insulet from $331.00 to $353.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Jefferies Financial Group reissued a "buy" rating on shares of Insulet in a research report on Thursday, August 7th. Barclays boosted their price objective on Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a research report on Thursday. Wolfe Research raised Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price objective for the company in a research report on Tuesday, May 13th. Finally, Wells Fargo & Company boosted their price objective on Insulet from $330.00 to $350.00 and gave the stock an "overweight" rating in a research report on Friday, August 8th. Sixteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Insulet currently has a consensus rating of "Moderate Buy" and an average price target of $332.71.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.